BridgeBio Pharma, Inc.

NASDAQ:BBIO

Biotechnology

Healthcare
$78.01 +1.13%

+$0.75 today

Market cap
$15.20B
Beta
0.97
P/E (TTM)
-18.1
EPS (TTM)
-$3.73
52W Low $40.19High $84.94

Volume 3.55M

Average 2.49M

BBIO Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

BridgeBio Pharma, Inc.NASDAQ: BBIO

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation growth accelerates

Q2 FY2026 stock-based compensation of $44.07M rose 18.3% year over year, ahead of the -7.0% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 32.6% from the prior quarter. Over 3 fiscal years it compounded at +13.3% a year.

Context

  • Stock-based compensation amounted to 26.5% of revenue in FY2025, down 16.7 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +18.3% holds above the trailing-twelve-month pace of -7.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$44.07M+32.6% QoQ
Last fiscal yearDec 2025
$133.02M+38.9% YoY
LTMJun 2026
$111.95M-7.0% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+18.3%——
1 year+38.9%——
3-year CAGR+13.3%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
133.02M USD
Year-over-year change
+38.9%
4-year CAGR
+7.5%

Stock-Based Compensation vs competitors

How BBIO compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -7.0% is the 9th highest of 11, against a peer median of +14.8%.
  • Stock-based compensation amounts to 15.7% of revenue for BBIO, versus a peer median of 15.3%.
BBIO Competitors
Stock-Based Compensation for BBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$172.73B USD+92559.3%-2.6%16.8%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$336.62M USD+10.1%+14.7%7.0%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$142.83M USD-11.3%+5.5%21.3%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$132.29M USD+4.4%+10.1%13.8%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026$111.95M USD-7.0%+13.3%15.7%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$84.66M USD+15.0%-12.3%8.4%
SRRKScholar Rock Holding CorporationLTM Sep 2026$75.24M USD+14.6%+39.7%13200.2%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$72.84M USD+70.9%+5.6%11.2%
DNLIDenali Therapeutics Inc.LTM Jun 2026$69.95M USD+39.2%-0.1%1941.0%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$20.28M USD+92.0%+34.5%101.4%
ASNDAscendis Pharma A/SLTM Sep 2026€0 EUR-100.0%—0.0%
Peer median (excluding BBIO) —+14.8%+5.6%15.3%

Competitors are the stored peer set for BBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(586.45M)(484.65M)(643.2M)(543.35M)(724.93M)
Depreciation & Amortization5.84M6.77M6.49M6.08M5.43M
Deferred Income Tax(30.93M)0000
Stock-Based Compensation99.51M91.56M095.8M133.02M
Change in Working Capital(4.4M)28.08M5.06M32.04M(51.06M)
Accounts Receivables(19.75M)15.17M15.33M(2.97M)(134.72M)
Inventory19.75M000(25.31M)
Accounts Payables2.83M(349K)2.78M1.51M26.61M
Other Working Capital(7.23M)13.26M(13.05M)33.5M82.36M
Other Non-Cash Items18.5M(61.25M)103.93M(111.3M)191.63M
Operating Cash Flow(497.93M)(419.49M)(527.72M)(520.73M)(445.91M)
Capital Expenditures(48.25M)(6.32M)(1.31M)(933K)(1.1M)
Acquisitions (Net)(35M)00(140K)0
Purchases of Investments(643.28M)(193.06M)(137.26M)(88.4M)(28.2M)
Sales of Investments477.04M532.52M193.11M158.23M11M
Other Investing Activities48.65M118.5M(503K)(7.98M)(6.19M)
Investing Cash Flow(200.83M)453.15M54.03M60.78M(24.49M)
Debt Repayment1.08B(20.49M)0476.58M385.5M
Common Stock Issued04.85M449.81M314.74M34.15M
Common Stock Repurchased(204.75M)(1.56M)(6.88M)(7.53M)(48.28M)
Dividends Paid00000
Other Financing Activities(138.49M)4.06M8.61M(35.34M)(12.08M)
Financing Cash Flow736.45M(13.13M)451.54M748.46M359.29M
Effect of Forex Changes00000
Net Change in Cash37.69M20.52M(22.15M)288.51M(111.1M)
Free Cash Flow(546.18M)(425.82M)(529.03M)(521.66M)(447.01M)

BridgeBio Pharma, Inc.

NASDAQ:BBIO

Intrinsic Alpha fair value

Locked

Current Price

$78.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.